NASD · Healthcare · Health Information Services · USA
DarioHealth Corp is a micro cap company (market value under $300 million) in the Health Information Services industry.
DarioHealth is a vertically integrated health intelligence platform combining connected hardware devices, artificial intelligence, and behavior change coaching for chronic condition management. The company serves employers, health plans, and pharmaceutical companies through a subscription model, addressing diabetes, hypertension, obesity, and mental health through digital self-care with virtual coaching and clinical services.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the DarioHealth Corp stock.
No reliable verdict: intrinsic value $56.58 per share, market price $1.15 (as of 2026-11-17).
Its earnings through the cycle, capitalised at its cost of capital, would put the shares at $56.58: 49 times the price of $1.15. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
All 40 Health Information Services stocks
We do not publish a verdict on DRIO. Its earnings through the cycle, capitalised at its cost of capital, would put the shares at $56.58: 49 times the price of $1.15. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
We do not publish one (as of the 2026-11-17 close). Its earnings through the cycle, capitalised at its cost of capital, would put the shares at $56.58: 49 times the price of $1.15. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.